Literature DB >> 14963139

Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques.

Magdalena Magierowska1, Flavien Bernardin, Seema Garg, Silvija Staprans, Michael D Miller, Koen K A Van Rompay, Eric L Delwart.   

Abstract

Antiviral tenofovir monotherapy was used to determine whether drug-selected simian immunodeficiency virus (SIV) variants replaced their wild-type progenitors at the same rate in different tissues of six rhesus macaques. The relative frequencies of drug-resistant and wild-type genotypes were measured longitudinally in blood and in 23 lymphoid and nonlymphoid tissues collected at necropsy. The mutant/wild-type genotype ratio was measured using a heteroduplex tracking assay targeting tenofovir-selected SIV reverse transcriptase codons. After the initiation of tenofovir treatment in animals with high steady-state viremia levels, resistant genotypes emerged in the plasma within 1 to 8 weeks and in five of six cases reached frequencies of nearly 100% within 4 to 25 weeks. The appearance of tenofovir-resistant genotypes in peripheral blood mononuclear cell (PBMC) DNA was generally delayed by 1 to 2 weeks and in one case was completely absent. Necropsies performed 8 to 55 weeks after the initiation of tenofovir treatment showed the frequency of resistant SIV genotypes to be generally higher in tissue RNA than DNA fractions. The frequency of drug-resistant genotypes varied widely between anatomical sites, including different lymph nodes of the same animal. Except for the epidydimis, the tissues with the lowest rates of proviral replacement by tenofovir-resistant genotypes differed between animals. The highly uneven distribution of tenofovir-resistant genotypes in different tissues seen shortly after the initiation of tenofovir monotherapy may reflect differences in local antiviral drug selection pressures and/or the stochastic effect of small effective populations of drug-resistant variants randomly seeding different anatomical sites early in therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14963139      PMCID: PMC369237          DOI: 10.1128/jvi.78.5.2434-2444.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

Review 1.  Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.

Authors:  T Pierson; J McArthur; R F Siliciano
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Genetic diversity of primary HIV-1 isolates and their sensitivity to antibody-mediated neutralization.

Authors:  C J Gordon; E L Delwart
Journal:  Virology       Date:  2000-07-05       Impact factor: 3.616

3.  Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies.

Authors:  A Ibáñez; B Clotet; M A Martínez
Journal:  J Gen Virol       Date:  2000-01       Impact factor: 3.891

4.  Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.

Authors:  K K Van Rompay; M D Miller; M L Marthas; N A Margot; P J Dailey; D R Canfield; R P Tarara; J M Cherrington; N L Aguirre; N Bischofberger; N C Pedersen
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Simian immunodeficiency virus mac251 infection of astrocytes.

Authors:  G Guillemin; J Croitoru; R L Le Grand; M Franck-Duchenne; D Dormont; F D Boussin
Journal:  J Neurovirol       Date:  2000-06       Impact factor: 2.643

6.  Activated memory CD4(+) T helper cells repopulate the intestine early following antiretroviral therapy of simian immunodeficiency virus-infected rhesus macaques but exhibit a decreased potential to produce interleukin-2.

Authors:  J J Mattapallil; Z Smit-McBride; P Dailey; S Dandekar
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.

Authors:  K K Van Rompay; J M Cherrington; M L Marthas; P D Lamy; P J Dailey; D R Canfield; R P Tarara; N Bischofberger; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

8.  Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

Authors:  R Schuurman; M Nijhuis; R van Leeuwen; P Schipper; D de Jong; P Collis; S A Danner; J Mulder; C Loveday; C Christopherson
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

9.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

10.  In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.

Authors:  M A Wainberg; M D Miller; Y Quan; H Salomon; A S Mulato; P D Lamy; N A Margot; K E Anton; J M Cherrington
Journal:  Antivir Ther       Date:  1999
View more
  6 in total

1.  Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.

Authors:  Koen K A Van Rompay; Raman P Singh; Walid Heneine; Jeffrey A Johnson; David C Montefiori; Norbert Bischofberger; Marta L Marthas
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.

Authors:  Koen K A Van Rompay; Raman P Singh; Bapi Pahar; Donald L Sodora; Casey Wingfield; Jonathan R Lawson; Marta L Marthas; Norbert Bischofberger
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

3.  Antiretrovirals to prevent HIV infection: pre- and postexposure prophylaxis.

Authors:  Cynthia L Gay; Myron S Cohen
Journal:  Curr Infect Dis Rep       Date:  2008-07       Impact factor: 3.725

4.  Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.

Authors:  Koen K A Van Rompay; Kristin A Trott; Kartika Jayashankar; Yongzhi Geng; Celia C LaBranche; Jeffrey A Johnson; Gary Landucci; Jonathan Lipscomb; Ross P Tarara; Don R Canfield; Walid Heneine; Donald N Forthal; David Montefiori; Kristina Abel
Journal:  Retrovirology       Date:  2012-07-17       Impact factor: 4.602

5.  Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.

Authors:  J Gerardo García-Lerma; Ron A Otten; Shoukat H Qari; Eddie Jackson; Mian-Er Cong; Silvina Masciotra; Wei Luo; Caryn Kim; Debra R Adams; Michael Monsour; Jonathan Lipscomb; Jeffrey A Johnson; David Delinsky; Raymond F Schinazi; Robert Janssen; Thomas M Folks; Walid Heneine
Journal:  PLoS Med       Date:  2008-02       Impact factor: 11.069

6.  Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients.

Authors:  Amit Kapoor; Beth Shapiro; Robert W Shafer; Nancy Shulman; Soo-Yon Rhee; Eric L Delwart
Journal:  Retrovirology       Date:  2008-01-25       Impact factor: 4.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.